Get the Daily Brief
Latest Biotech News
Optogenetic Platform RELISR Controls Protein and mRNA in Cells
A KAIST research team developed RELISR, an optogenetic platform enabling precise spatiotemporal control over the storage and release of proteins and mRNAs in living cells and animals. This...
Atai Shifts Focus After Schizophrenia Drug Failure
Atai Life Sciences' subsidiary Recognify Life Sciences experienced a setback when its schizophrenia drug candidate, inidascamine, failed to meet the primary cognitive improvement endpoint in a...
Natera’s Signatera Drives Market Leadership in MRD Testing
Natera attracted Evercore ISI’s Outperform rating and a $170 price target on recognition of its leading position in the minimal residual disease (MRD) detection market through its Signatera test....
Revvity Posts 4% Revenue Growth Fueled by Diagnostics and Life Sciences
Revvity reported a 4% year-over-year increase in second-quarter revenues to $720.3 million, driven by growth in diagnostics and life sciences sectors. Diagnostics revenue rose 3% amid...
GSK Invests $500M in Hengrui to Expand COPD Pipeline
GlaxoSmithKline (GSK) agreed to pay $500 million upfront for rights to a clinical-stage COPD drug, HRS-9821, from Chinese pharmaceutical company Jiangsu Hengrui Pharmaceuticals. The transaction is...
Celcuity’s Phase 3 Breast Cancer Combo Nears FDA Submission
Celcuity reported successful Phase 3 trial results for its breast cancer combination therapy gedatolisib, which delayed tumor progression and met primary endpoints in relevant patient populations....
Abivax Shares Surge on Ulcerative Colitis Phase 3 Data and Fundraising
Abivax energized investor interest after reporting strong Phase 3 data for its oral ulcerative colitis candidate obefazimod, exceeding prior expectations. The company successfully launched a...
FDA Rejection Signals Changing Oncology Regulatory Landscape for RP1
The FDA issued a complete response letter for Replimune’s RP1 oncolytic virus therapy, leading to a rapid 75% stock plunge. RP1 is an immuno-oncology candidate targeting anti-PD-1 refractory...
Mass Ivermectin Use Cuts Malaria Transmission in Kenya Trial
The BOHEMIA trial demonstrated a 26% reduction in new malaria infections following mass administration of ivermectin to children aged 5–15 in Kenya, complementing bed net use. Ivermectin’s...
Re-Vana and Boehringer Ink $1B Pact for Eye Drug Delivery Tech
Boehringer Ingelheim entered a collaboration agreement with Re-Vana Therapeutics centered on Re-Vana’s ocular extended-release drug delivery platform aimed at reducing injection frequency for...
New Insights into Mitophagy Pathways Open Parkinson’s Therapy Avenues
University of Vienna researchers elucidated distinct mechanisms by which transmembrane cargo receptors initiate mitophagy, the selective degradation of mitochondria linked to neurodegenerative...
GSK’s $12B Deal: China’s Hengrui Powers COPD Pipeline
GSK has entered a sweeping licensing agreement with China's Jiangsu Hengrui Pharmaceuticals worth up to $12 billion, including a $500 million upfront payment. The deal covers 12 drug programs...
Celcuity’s Breast Cancer Combo Wins Phase 3 — FDA Filing Next
Celcuity has reported positive Phase 3 clinical trial data for its breast cancer combination therapy, achieving primary endpoints with a significant reduction in mortality risk in certain patient...
FDA Investigates Safety of Sarepta’s Elevidys Gene Therapy
The FDA has initiated an investigation into the death of an 8-year-old Brazilian boy following treatment with Elevidys, Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy. In...
Replimune’s $900M Oncolytic Virus Faces FDA Setback
Replimune's RP1 oncolytic virus therapy, designed for anti-PD-1 refractory melanoma, received a complete response letter from the FDA, signaling a significant regulatory hurdle despite encouraging...
Abivax Shares Rally on Phase III Ulcerative Colitis Data, $747M Raise
French biotech Abivax surged after its oral ulcerative colitis drug obefazimod exceeded Phase III expectations. The company raised $747.5 million through a Nasdaq offering, oversubscribed five...
Ivermectin Mass Administration Cuts Malaria Transmission in Kenya
A large cluster-randomized trial in Kwale, Kenya, demonstrated that monthly mass administration of ivermectin reduced malaria infections by 26% in children aged 5–15. Published in The New England...
Mitophagy Pathways Uncovered: New Therapy Avenue for Parkinson’s
Researchers at the University of Vienna detailed molecular mechanisms initiating mitophagy through transmembrane cargo receptors, offering insights into selective mitochondrial degradation....
GenAI and Real-World Data: 4 Keys to Pharma Insights
Pharma companies deploying AI-powered real-world data analytics must prioritize platform usability, data agnosticism, transparency, and flexibility to generate actionable insights. Effective GenAI...
Theta-Frequency DBS Enhances Cognitive Control in Parkinson’s
Neuroscientists have demonstrated that theta-frequency deep brain stimulation targeting basal ganglia areas can improve conflict resolution and cognitive functions in Parkinson’s disease patients....